Overview

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstructio

Status:
Completed

Trial end date:
2017-04-19

Target enrollment:

Participant gender:

Summary

The purpose of this Phase II study is to assess the safety, reactogenicity and immunogenicity of the investigational Non-typeable Haemophilus influenzae (NTHi) vaccine in patients with moderate and severe persistent airflow obstruction.

Phase:

Phase 2

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Vaccines